{"id":934,"date":"2024-08-06T14:03:59","date_gmt":"2024-08-06T14:03:59","guid":{"rendered":"https:\/\/euprtoday.com\/vers-un-nouveau-scandale-sanitaire\/"},"modified":"2024-08-06T14:03:59","modified_gmt":"2024-08-06T14:03:59","slug":"vers-un-nouveau-scandale-sanitaire","status":"publish","type":"post","link":"https:\/\/euprtoday.com\/fr\/vers-un-nouveau-scandale-sanitaire\/","title":{"rendered":"vers un nouveau scandale sanitaire\u00a0?"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div>\n<p>\n\t\t\t<span class=\"articleHead-readingTimeText\">Temps de lecture:<\/span><\/p>\n<p>    <span class=\"chip    blue\"><br \/>\n                <span class=\"chip-content\"><\/p>\n<p>\t\t<svg class=\"icon icon-chrono\" aria-hidden=\"true\" focusable=\"false\">\n\t\t<use href=\"#chrono\"\/>\n\t<\/svg><\/p>\n<p>                1 min<\/p>\n<p>                    <\/span><br \/>\n    <\/span><\/p>\n<p class=\"articleHead-lead\">\n\t\t\tL\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA) a ordonn\u00e9 l\u2019arr\u00eat de la commercialisation de 400 m\u00e9dicaments. Il s\u2019agit de formes g\u00e9n\u00e9riques qui ont re\u00e7u une \u00e9valuation favorable de Synapse Labs. Or, il s\u2019av\u00e8re que l\u2019organisme de recherches sous contrat indien \u00abn&rsquo;est pas consid\u00e9r\u00e9 comme fiable\u00bb, a fait savoir l\u2019EMA.\n\t\t<\/p>\n<\/p><\/div>\n<div id=\"article-lead-js\">\n<p>\n\t\t\t\tVid\u00e9o Capital : L&rsquo;Europe retire 400&#8230;<\/p>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.capital.fr\/economie-politique\/l-europe-retire-400-medicaments-du-marche-vers-un-nouveau-scandale-sanitaire-1498452\">Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Temps de lecture: 1 min L\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA) a ordonn\u00e9 l\u2019arr\u00eat de la commercialisation de 400 m\u00e9dicaments. Il s\u2019agit de formes g\u00e9n\u00e9riques qui ont re\u00e7u une \u00e9valuation favorable de Synapse Labs. Or, il s\u2019av\u00e8re que l\u2019organisme de recherches sous contrat indien \u00abn&rsquo;est pas consid\u00e9r\u00e9 comme fiable\u00bb, a fait savoir l\u2019EMA. Vid\u00e9o Capital : [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[67],"tags":[],"class_list":{"0":"post-934","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-marketing"},"_links":{"self":[{"href":"https:\/\/euprtoday.com\/fr\/wp-json\/wp\/v2\/posts\/934","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/euprtoday.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/euprtoday.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/euprtoday.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/euprtoday.com\/fr\/wp-json\/wp\/v2\/comments?post=934"}],"version-history":[{"count":0,"href":"https:\/\/euprtoday.com\/fr\/wp-json\/wp\/v2\/posts\/934\/revisions"}],"wp:attachment":[{"href":"https:\/\/euprtoday.com\/fr\/wp-json\/wp\/v2\/media?parent=934"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/euprtoday.com\/fr\/wp-json\/wp\/v2\/categories?post=934"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/euprtoday.com\/fr\/wp-json\/wp\/v2\/tags?post=934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}